Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week High – Should You Buy?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $15.15 and last traded at $15.1920, with a volume of 32705 shares. The stock had previously closed at $14.82.

Analysts Set New Price Targets

AMRX has been the topic of several analyst reports. Truist Financial set a $15.00 price target on Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Barclays started coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and set a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $13.80.

Amneal Pharmaceuticals Trading Up 2.5%

The stock has a market cap of $4.78 billion, a price-to-earnings ratio of 760.13 and a beta of 1.36. The firm’s 50-day moving average is $13.34 and its two-hundred day moving average is $11.37.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kemnay Advisory Services Inc. purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth about $26,000. Federated Hermes Inc. lifted its stake in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares in the last quarter. Comerica Bank boosted its holdings in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the last quarter. Exchange Traded Concepts LLC purchased a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $31,000. Finally, Spire Wealth Management grew its position in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after purchasing an additional 1,023 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.